Login to Your Account

Numab Regains Asthma Bispecific Antibody Fragment from Sucampo

By Cormac Sheridan
Staff Writer

Tuesday, October 29, 2013
Early stage fragment antibody developer Numab AG has regained control of a drug development program in severe asthma it originally licensed to Sucampo Pharmaceuticals Inc. more than two years ago and is now seeking Series A funding to take forward that molecule, ND003, as well as a second drug candidate, ND007, which is in development for autoimmune indications.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription